drugset
Drugs / Cystic fibrosis transmembrane conductance regulator
last change Nov 2002 re-read 3 minutes ago

Cystic fibrosis transmembrane conductance regulator

Other / unclassified targets CFTR

Developed for
cystic fibrosis
Investigated by
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · University of Alabama at Birmingham

Trials 1

today NCT00004806 · Ph 1
199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00004806 Jun 1995 → Nov 2002 cystic fibrosis University of Alabama at Birmingham Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Cystic fibrosis transmembrane conductance regulator ClinicalTrials.gov intervention name — accepted as the source's own label NCT00004806 ↗
Modality Other / unclassified “lipid-mediated transfer of the cystic fibrosis transmembrane conductance regulator gene” NCT00004806 ↗
Route Intranasal “is administered intranasally to the right inferior turbinate” NCT00004806 ↗
Target CFTR “Cystic fibrosis transmembrane conductance regulator (CFTR) gene complexed with lipid” NCT00004806 ↗